UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 119

Sortiert nach

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

Journal of clinical oncology, 2018-04, Vol.36 (11), p.1080-1087

2018

Volltextzugriff (PDF)

The distribution of esophageal cancer patients enrolled in care at the Uganda Cancer Institute by sub-regions, districts and ethnicity

African health sciences, 2024-03, Vol.24 (1), p.198-205

2024

Volltextzugriff (PDF)

Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?

Journal of clinical oncology, 2007-07, Vol.25 (21), p.2993-2995

2007

Volltextzugriff (PDF)

Characteristics and outcomes of patients with multiple myeloma at the Uganda Cancer Institute

African health sciences, 2021-03, Vol.21 (1), p.67-74

2021

Volltextzugriff (PDF)

Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis

Current opinion in hematology, 2007-09, Vol.14 (5), p.468-480

2007

Volltextzugriff (PDF)

Drug Insight: vascular disrupting agents and angiogenesis-novel approaches for drug delivery

Nature clinical practice. Oncology, 2006-12, Vol.3 (12), p.682-692

2006

Volltextzugriff (PDF)

Clinicopathological characteristics and treatment outcomes of oesophageal cancer patients in Uganda

Ecancermedicalscience, 2023, Vol.17, p.1576-1576

2023

Volltextzugriff (PDF)

Toxicity of sunitinib plus bevacizumab in renal cell carcinoma

Journal of clinical oncology, 2010-06, Vol.28 (17), p.e284-e285

2010

Volltextzugriff (PDF)

Operational Metrics for the ELAINE 2 Study Combining a Traditional Approach With a Just-in-TIME Model

JCO clinical cancer informatics, 2023-06, Vol.7, p.e2200164

2023

Volltextzugriff (PDF)

MP84-15 NATIONAL TRENDS OF LOCAL ABLATIVE THERAPY AMONG YOUNG PATIENTS WITH SMALL RENAL MASSES

The Journal of urology, 2015-04, Vol.193 (4), p.e1064-e1064

2015

Volltextzugriff (PDF)

Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists?

Journal of clinical oncology, 2006-04, Vol.24 (10), p.1485-1488

2006

Volltextzugriff (PDF)

Phase 2 Trial of Pemetrexed Disodium and Gemcitabine in Advanced Urothelial Cancer (E4802) : A Trial of the Eastern Cooperative Oncology Group

Cancer, 2008-06, Vol.112 (12), p.2671-2675

2008

Volltextzugriff (PDF)

High-Grade Transitional Cell Carcinoma and Melanosis of Urinary Bladder: Case Report and Review of the Literature

Urology (Ridgewood, N.J.), 2009-04, Vol.73 (4), p.928.e13-928.e15

2009

Volltextzugriff (PDF)

A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma

Investigational new drugs, 2012-02, Vol.30 (1), p.364-367

2012

Volltextzugriff (PDF)

The Tempus TIME trial portal and clinical trial enrollment

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.1583-1583

2023

Volltextzugriff (PDF)

Pilot study for the use of wearable devices for patients undergoing oral chemotherapy

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e14103-e14103

2020

Volltextzugriff (PDF)

The TIME Trial Network to facilitate rapid clinical trial activation, patient screening, and enrollment in molecularly targeted trials

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.1563-1563

2021

Volltextzugriff (PDF)

Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.5081-5081

2022

Volltextzugriff (PDF)

Operational metrics for the ELAINE II study combining a traditional approach with a just-in-time model

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.1504-1504

2022

Volltextzugriff (PDF)

Leveraging machine learning technology to efficiently identify and match patients for precision oncology clinical trials

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e13588-e13588

2021

Volltextzugriff (PDF)

Patterns of metastases, treatment (tx), and outcomes in bone predominant (BP) metastatic urothelial carcinoma (mUC)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e16523-e16523

2018

Volltextzugriff (PDF)

Outcomes in bone predominant (BP) urothelial carcinoma (UC)

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.441-441

2018

Volltextzugriff (PDF)

Prostate cancer burden at the Uganda Cancer Institute (UCI)

Journal of clinical oncology, 2015-03, Vol.33 (7_suppl), p.246-246

2015

Volltextzugriff (PDF)

Promising systemic therapy for renal cell carcinoma

Current treatment options in oncology, 2005-10, Vol.6 (5), p.357-365

2005

Volltextzugriff (PDF)

HCRN GU14-188: Neoadjuvant pembrolizumab (P) and gemcitabine (G) with or without cisplatin (C) in muscle invasive urothelial cancer (MIUC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS4578-TPS4578

2016

Volltextzugriff (PDF)

1 – 25 von 119

Suche als RSS-Feed

Aktive Filter

ThemaAdult

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(109)
Mit Volltextzugriff
(111)

Publikationsform

Sprache

Englisch
(119)
Japanisch
(17)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

The distribution of esophageal cancer patients enrolled in care at the Uganda Cancer Institute by sub-regions, districts and ethnicity

Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?

Characteristics and outcomes of patients with multiple myeloma at the Uganda Cancer Institute

Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis

Drug Insight: vascular disrupting agents and angiogenesis-novel approaches for drug delivery

Clinicopathological characteristics and treatment outcomes of oesophageal cancer patients in Uganda

Toxicity of sunitinib plus bevacizumab in renal cell carcinoma

Operational Metrics for the ELAINE 2 Study Combining a Traditional Approach With a Just-in-TIME Model

MP84-15 NATIONAL TRENDS OF LOCAL ABLATIVE THERAPY AMONG YOUNG PATIENTS WITH SMALL RENAL MASSES

Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists?

Phase 2 Trial of Pemetrexed Disodium and Gemcitabine in Advanced Urothelial Cancer (E4802) : A Trial of the Eastern Cooperative Oncology Group

High-Grade Transitional Cell Carcinoma and Melanosis of Urinary Bladder: Case Report and Review of the Literature

A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma

The Tempus TIME trial portal and clinical trial enrollment

Pilot study for the use of wearable devices for patients undergoing oral chemotherapy

The TIME Trial Network to facilitate rapid clinical trial activation, patient screening, and enrollment in molecularly targeted trials

Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial

Operational metrics for the ELAINE II study combining a traditional approach with a just-in-time model

Leveraging machine learning technology to efficiently identify and match patients for precision oncology clinical trials

Patterns of metastases, treatment (tx), and outcomes in bone predominant (BP) metastatic urothelial carcinoma (mUC)

Outcomes in bone predominant (BP) urothelial carcinoma (UC)

Prostate cancer burden at the Uganda Cancer Institute (UCI)

Promising systemic therapy for renal cell carcinoma

HCRN GU14-188: Neoadjuvant pembrolizumab (P) and gemcitabine (G) with or without cisplatin (C) in muscle invasive urothelial cancer (MIUC)

Aktive Filter

Suchergebnisse filtern